Involvement of adiponectin in early stage of colorectal carcinogenesis

BMC Cancer

Chung Hyun Tae⁴  Seong-Eun Kim⁴  Sung-Ae Jung⁴  Yang-Hee Joo⁴  Ki-Nam Shim⁴  Hye-Kyung Jung⁴  Tae Hun Kim⁴  Min-Sun Cho¹  Kwang Ho Kim²  Joung Sook Kim³ 

[1] Department of Pathology, Ewha Medical Research Institue, Ewha Womans University School of Medicine, Seoul, Korea

[2] Department of Surgery, Ewha Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea

[3] Department of Health Promotion Medicine, Ewha Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea

[4] Department of Internal Medicine, Ewha Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea

关键词: Carcinogenesis;    Colorectal cancer;    Adiponectin receptors;    Adiponectin;   

Others  :  1120234
DOI  :  10.1186/1471-2407-14-811

 received in 2013-08-18, accepted in 2014-10-23,  发布年份 2014

【 摘 要 】

Background

Although altered levels of adiponectin have been reported as a potential risk factor in colorectal cancer (CRC), the importance of the role played by adiponectin in colorectal carcinogenesis has not been established. We sought to examine the expression pattern of adiponectin and adiponectin receptors (AdipoRs) in the normal-adenoma-carcinoma sequence and to assess the implications of adiponectin in colorectal carcinogenesis.

Methods

Serum adiponectin concentrations, and the mRNA and protein expression of adiponectin and AdipoRs were examined using serum and tissues from patients with CRC, advanced adenoma, and a normal colon. mRNA expression of AdipoRs and epithelial-mesenchymal transition regulators including E-cadherin, cyclooxygenase-2 (COX-2) and T-cadherin were examined in HCT116 cells treated with adiponectin.

Results

Serum adiponectin concentrations in patients with advanced adenoma and CRC were lower than those in controls. Adiponectin mRNA was not detected in colonic tissue, whereas AdipoRs mRNA was lower in advanced adenoma and CRC than that in normal colon tissues. Immunohistochemical staining demonstrated that adiponectin was expressed in spindle-shaped cells of the subepithelial layer in normal colon tissues, whereas ill-defined overexpression of adiponectin was seen in the stroma of advanced adenoma and CRC tissues. AdipoRs expression was strong in normal epithelium, but weak to negative in the epithelia of CRC tissues. Adiponectin downregulated COX-2 mRNA expression in vitro, but upregulated T-cadherin in HCT116 cells.

Conclusions

Systemic adiponectin and local AdipoRs expression in the colon may be associated with anti-tumorigenesis during the early stages of CRC. These findings offer new insight into understanding the relationship between adiponectin and colorectal carcinogenesis.

【 授权许可】

   
2014 Tae et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2007, 92(03):347.
• [2]Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221(2):286-289.
• [3]Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271(18):10697-10703.
• [4]Goldfine AB, Kahn CR: Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003, 362(9394):1431-1432.
• [5]Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(3):439-451.
• [6]Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20(6):1595-1599.
• [7]Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM: Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001, 288(5):1102-1107.
• [8]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257(1):79-83.
• [9]Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100(25):2473-2476.
• [10]Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89(6):2548-2556.
• [11]Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101(28):10308-10313.
• [12]Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348(17):1625-1638.
• [13]Kolonel LN, Altshuler D, Henderson BE: The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004, 4(7):519-527.
• [14]Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371(9612):569-578.
• [15]Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D: Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89(3):1102-1107.
• [16]Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C: Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004, 89(3):1160-1163.
• [17]Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK: Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010, 52(5):1713-1722.
• [18]Perrier S, Jarde T: Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem 2012, 19(32):5501-5512.
• [19]Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB: Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010, 24(7):1441-1452.
• [20]Ogunwobi OO, Beales IL: Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006, 134(2–3):105-113.
• [21]Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS: Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97(22):1688-1694.
• [22]Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P: Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(2):401-402.
• [23]Yoneda K, Tomimoto A, Endo H, Iida H, Sugiyama M, Takahashi H, Mawatari H, Nozaki Y, Fujita K, Yoneda M, Inamori M, Nakajima N, Wada K, Nagashima Y, Nakagama H, Uozaki H, Fukayama M, Nakajima A: Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep 2008, 20(3):479-483.
• [24]Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, Tseleni-Balafouta S, Mantzoros CS: Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer 2008, 15(1):289-299.
• [25]Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D: miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One 2013, 8(6):e66502.
• [26]World Health Organisation, International Association for the Study of Obesity, International Obesity Task Force: The Asia-Pacific Perspective Redefining obesity and its treatment. Health Communications; 2000.
• [27]Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, Xiao SD: Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis 2011, 12(4):234-244.
• [28]Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, Saito T, Togashi H, Nakamura T, Matsuzawa Y, Kawata S: Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 2005, 11(10):3642-3646.
• [29]Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, Kawata S: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 2010, 16(10):1252-1257.
• [30]Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M: Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study. Diabet Med 2008, 25(6):747-750.
• [31]Adamczak M, Rzepka E, Chudek J, Wiȩcek A: Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 2005, 62(1):114-118.
• [32]Durand JL, Nawrocki AR, Scherer PE, Jelicks LA: Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase. J Cell Biochem 2012, 29(10):24206.
• [33]Lilja M, Rolandsson O, Norberg M, Soderberg S: The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance. Metab Syndr Relat Disord 2012, 10(2):143-151.
• [34]Tabatabaei-Malazy O, Hasani-Ranjbar S, Amoli MM, Heshmat R, Sajadi M, Derakhshan R, Amiri P, Namakchian M, Rezazadeh E, Tavakkoly-Bazzaz J, Keshtkar A, Larijani B: Gender-specific differences in the association of adiponectin gene polymorphisms with body mass index. Rev Diabet Stud 2010, 7(3):241-246.
• [35]Kern PA, Gregorio GBD, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-a expression. Diabetes 2003, 52:1779-1785.
• [36]Wang Y, Lam KSL, Xu A: Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 2007, 17(4):280-282.
• [37]Obeid S, Hebbard L: Role of adiponectin and its receptors in cancer. Cancer Biol Med 2012, 9(4):213-220.
• [38]Dalamaga M, Diakopoulos KN, Mantzoros CS: The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012, 33(4):547-594.
• [39]Gialamas SP, Petridou ET, Tseleni-Balafouta S, Spyridopoulos TN, Matsoukis IL, Kondi-Pafiti A, Zografos G, Mantzoros CS: Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011, 60(11):1530-1538.
• [40]Fenton JI, Birmingham JM: Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol carcinog 2010, 49(7):700-709.
• [41]Moon H-S, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, Hatziapostolou M, Wu Y, Robson SC, Iliopoulos D, Mantzoros CS: Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut 2013, 62(4):561-570.
• [42]Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, Kim JG, Yang SK, Kim JH, Suh DJ: Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 2010, 127(12):2758-2767.
• [43]Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A: Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008, 57(11):1531-1538.
• [44]Mifflin RC, Pinchuk IV, Saada JI, Powell DW: Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol 2011, 300:G684-G696.
• [45]Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Gkermpesi M, Sotiropoulou-Bonikou G, Papavassiliou AG: EGF-R is expressed and AP-1 and NF-κB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Anal Cell Pathol 2007, 29(6):477-482.
• [46]Alexis D, Christelle G, Giulio G: The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004, 48:509-517.
• [47]Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E: Epithelial-mesenchymal transition. Cancer Res 2008, 68(23):9574-9577.
• [48]Takeuchi T, Adachi Y, Ohtsuki Y, Furihata M: Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol 2007, 40(3):115-120.
• [49]Berx G, van Roy F: Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspect Biol 2009, 1:6.
• [50]J-z R, J-r H: Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells. Med Oncol 2012, 29(2):915-918.
• [51]Hwang J-T, Ha J, Park I-J, Lee S-K, Baik HW, Kim YM, Park OJ: Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 2007, 247(1):115-121.
• [52]Vetvik KK, Sonerud T, Lindeberg M, Luders T, Storkson RH, Jonsdottir K, Frengen E, Pietilainen KH, Bukholm I: Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. Metabolism 2014, 63(5):672-681.